Clinical Trials

Verified stories whose regulatory record supports clinical-trial access. Eligibility and enrollment are never guaranteed.

Filter clinical trials

Results

97 verified trial-access stories match your filters.

Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.

Trial Watch: A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Lung Cancer
Trial identifier
NCT06623422
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Carcinoma, Non-Small-Cell Lung who meet the study-specific registry eligibility criteria.
Last reviewed
2026-09-28

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-09-28

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Lung Cancer
Trial identifier
NCT06931717
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Non-Small Cell Lung Cancer who meet the study-specific registry eligibility criteria.
Last reviewed
2026-09-28

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-09-28

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Multiple Myeloma
Trial identifier
NCT04923893
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Multiple Myeloma who meet the study-specific registry eligibility criteria.
Last reviewed
2026-09-25

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-09-25

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Lung Cancer
Trial identifier
NCT05132075
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants ages 18 Years to 100 Years with Non-Small Cell Lung Cancer who meet the study-specific registry eligibility criteria.
Last reviewed
2026-09-25

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-09-25

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Lymphoma
Trial identifier
NCT06091865
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Diffuse Large B-cell Lymphoma (DLBCL) who meet the study-specific registry eligibility criteria.
Last reviewed
2026-09-25

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-09-25

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator’s Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Head and Neck Cancer
Trial identifier
NCT06496178
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Head and Neck Squamous Cell Carcinoma who meet the study-specific registry eligibility criteria.
Last reviewed
2026-09-24

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-09-24

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Lung Cancer
Trial identifier
NCT05215340
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Metastatic Non Small Cell Lung Cancer who meet the study-specific registry eligibility criteria.
Last reviewed
2026-09-24

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-09-24

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Breast Cancer
Trial identifier
NCT04400695
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants ages 18 Years to 70 Years with Breast Cancer who meet the study-specific registry eligibility criteria.
Last reviewed
2026-09-23

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-09-23

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Breast Cancer
Trial identifier
NCT04989504
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Breast Carcinoma who meet the study-specific registry eligibility criteria.
Last reviewed
2026-09-23

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-09-23

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Endometrial (Uterine) Cancer
Trial identifier
NCT05256225
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma who meet the study-specific registry eligibility criteria; sex eligibility: female.
Last reviewed
2026-09-22

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-09-22

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.